WHAT is claimed to be the first commercially available compound library of novel small molecules to target deubiquitylase (dub) enzymes has been launched by Ubiquigent.
DUBtarget-001 has been developed with the University of Dundee, to support commercial and academic researchers entering the ubiquitin drug discovery field or with existing active programmes.
The company says it has already screened the library against USP2 (a dub with potential roles in oncology) and demonstrated a ‘significant number’ of hits from different structural classes.
These structures represent multiple starting points with the potential to lead to the development of novel therapeutic and tool compounds, it adds.
The library is now available in physical form for laboratory screening, or as a dataset for screening against any of the 40 other dub enzymes in Ubiquigent’s DUBprofile screening platform.
Ubiquigent’s executive chairman Dr Mark Treherne commented: “Dub-targeted libraries can unlock multiple therapeutic opportunities for the exploitation of novel dub inhibitors.
“DUBtarget-001 is the first of a pipeline of innovative libraries that will link ubiquitin research to new drug discovery opportunities for oncology, neurodegeneration and many other chronic diseases with significant unmet medical need.”